MedTrace Logo

Biology Studies of Hematologic Cancers

NCT00923442 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2026-04-27

No results posted yet for this study

Summary

This study will collect tumor samples from people with cancers of the blood, bone marrow, or lymph glands for laboratory study of the biology of these conditions. Such studies contribute to a better understanding of cancer biology and to the development of new treatments. Planned studies include:

* Examination of individual cancer cells and to search for differences compared to other types of cancer and normal cells
* Examination of the chromosomes and genes in cancer cells and to search for differences compared to other types of cancer and normal cells
* Development of sensitive methods to detect small amounts of cancer that remain after treatment
* Search for new cancer proteins that might serve as targets for treatment
* Investigation of methods to develop cancer vaccines.

Patients from \>= 1 to 75 years of age with acute lymphocytic leukemia, acute myelogenous leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, juvenile myelomonocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, and other hematologic malignancies may be eligible for this study.

Blood or bone marrow samples will be collected when sampling is required for the patient's medical care. Cells from some individuals will be grown in test tubes, establishing cell lines or in animals, establishing xenograft models. (A xenograft is transplantation of cells of one species to another species.)

Conditions

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • John W Glod, M.D. · National Cancer Institute (NCI)

Eligibility

Min Age
1 Year
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00923442 on ClinicalTrials.gov